Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease

Arthritis Care and Research

Volumn 63, Issue 5, 2011, Pages 729-734

  Crowson, Cynthia S ^a   Myasoedova, Elena ^a   Davis III, John M ^a   Roger, Veronique L ^a   Karon, Barry L ^a   Borgeson, Daniel ^a   Rodeheffer, Richard J ^a   Therneau, Terry M ^a   Gabriel, Sherine E ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROPORTIONAL HAZARDS MODEL; RHEUMATOID ARTHRITIS; SAMPLE; SCREENING; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 79958798451     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20425     Document Type: Article

References (31)

1. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010;62:1576-82.
2. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005;52:412-20. (Pubitemid 40216304)
3. Davis JM 3rd, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 2008;58:2603-11.
4. Liang KP, Myasoedova E, Crowson CS, Davis JM, Roger VL, Karon BL, et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis 2010;69:1665-70.
5. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004;29:707-69. (Pubitemid 39488317)
6. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993;132:1961-70. (Pubitemid 23133241)
7. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004;109:3176-81.
8. Giannoni A, Tani C, Clerico A, Passino C, Tavoni A, d'Ascanio A, et al. When the heart is burning: amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease. Int J Cardiol 2009. E-pub ahead of print.
9. Solus J, Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, et al. Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 2008;58:2662-9.
10. Harney SM, Timperley J, Daly C, Harin A, James T, Brown MA, et al. Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis [letter]. Ann Rheum Dis 2006;65:136. (Pubitemid 41815659)
11. Maradit Kremers H, Crowson CS, Gabriel SE. Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases. Rheum Dis Clin North Am 2004;30:819-34. (Pubitemid 39361475)
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
13. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202. (Pubitemid 36068707)
14. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82. (Pubitemid 34994995)
15. Richards M, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006;47:52-60. (Pubitemid 43005164)
16. Provan SA, Angel K, Odegard S, Mowinckel P, Atar D, Kvien TK. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther 2008;10:R70.
17. Haupl T, Burmester GR, Giannitsis E, Rohrlach T, Spanuth E, Parsch H, et al. N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis? [letter]. Ann Rheum Dis 2007;66:838-9. (Pubitemid 46846713)
18. Giannitsis E. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. Clin Lab 2005;51:63-83.
19. Peters MJ, Welsh P, McInnes IB, Wolbink GJ, Dijkmans BA, Sattar N, et al. TNFα blockade therapy reduces circulating NT-proBNP levels in RA patients with active disease: results from prospective cohort study. Ann Rheum Dis 2009;69:1281-5.
20. Corson MA. Emerging inflammatory markers for assessing coronary heart disease risk. Curr Cardiol Rep 2009;11:452-9.
21. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss C, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005;112:527-34. (Pubitemid 41060793)
22. Chen Y, Li C. Prognostic significance of brain natriuretic peptide obtained in the ED in patients with SIRS or sepsis. Am J Emerg Med 2009;27:701-6.
23. Vela-Zarate P, Varon J. BNP this, BNP that. . . Now in sepsis? [editorial]. Am J Emerg Med 2009;27:707-8.
24. Piechota M, Barylski M, Hannam S, Mikhailidis DP, Rysz J, Banach M. Natriuretic peptides in septic patients. Curr Med Chem 2009;16:4020-31.
25. Jacobs LH, van de Kerkhof JJ, Mingels AM, Passos VL, Kleijnen VW, Mazairac AH, et al. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Nephrol Dial Transplant 2010;25:243-8.
26. Casserly BP, Sears EH, Gartman EJ. The role of natriuretic peptides in inflammation and immunity. Recent Pat Inflamm Allergy Drug Discov 2010;4:90-104.
27. Shaw SM, Fildes JE, Puchalka CM, Basith M, Yonan N, Williams SG. BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro. Transpl Immunol 2009;20:199-202.
28. Omland T, Hagve TA. Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009;5:471-87.
29. Paganelli R, Di Iorio A, Cherubini A, Lauretani F, Mussi C, Volpato S, et al. Frailty of older age: the role of the endocrineimmune interaction. Curr Pharm Des 2006;12:3147-59. (Pubitemid 44227575)
30. Crowson CS, Liang KP, Therneau TM, Kremers HM, Gabriel SE. Could accelerated aging explain the excess mortality in patients with seropositive rheumatoid arthritis? Arthritis Rheum 2010;62:378-82.
31. Jacobsen SJ, Mahoney DW, Redfield MM, Bailey KR, Burnett JC Jr, Rodeheffer RJ. Participation bias in a population-based echocardiography study. Ann Epidemiol 2004;14:579-84. (Pubitemid 39221237)